E M Dijkgraaf1, S J A M Santegoets1, A K L Reyners2, R Goedemans1, M C A Wouters3, G G Kenter4, A R van Erkel5, M I E van Poelgeest6, H W Nijman2, J J M van der Hoeven1, M J P Welters1, S H van der Burg1, J R Kroep7. 1. Department of Clinical Oncology, Leiden University Medical Center, Leiden. 2. Department of Clinical Oncology. 3. Department of Gynecologic Oncology, University Medical Center Groningen, Groningen. 4. Department of Gynecologic Oncology, Center for Gynecological Oncology Amsterdam, Amsterdam. 5. Department of Radiology. 6. Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands. 7. Department of Clinical Oncology, Leiden University Medical Center, Leiden j.r.kroep@lumc.nl.
Abstract
BACKGROUND: The immune system is important in epithelial ovarian cancer (EOC). Interleukin-6 is associated with chemoresistance and an immune-suppressive tumor microenvironment. We investigated whether a combination of chemotherapeutics, blockade of interleukin6 (IL-6) receptor (IL-6R; tocilizumab), and immune enhancerinterferon-α (Peg-Intron) is feasible, safe, and able to enhance immunity in patients with recurrent EOC. PATIENTS AND METHODS: In this dose-escalation study, patients received tocilizumab 1, 2, 4, or 8 mg/kg i.v., q4 weeks during the first three cycles of carboplatin (AUC5) plus doxorubicin [pegylated liposomal doxorubicin (PLD) 30 mg/m(2) or doxorubicin 50 mg/m(2) i.v., day 1, q4 weeks, for six cycles]. At the highest tocilizumab dose (8 mg/kg), Peg-Intron (1 µg/kg s.c.) was added. Peripheral blood mononuclear cells were collected for immunomonitoring at baseline, after three and six cycles. Dose-limiting toxicity (DLT), CA-125, and radiologic response were evaluated. RESULTS: In the 23 patients enrolled, no DLT was established. The most frequent grade 3/4 adverse events (CTCAE v4.03) were neutropenia (23%), febrile neutropenia (19%), and ileus (19%). No treatment-related deaths occurred. Using CT evaluation, 11 of 21 assessable patients responded, 6 had stable disease and 3 progressive disease. Patients receiving highest dose tocilizumab showed a functional blockade of IL-6R with increased levels of serum IL-6 (P = 0.02) and soluble IL-6R (P = 0.008). Consequently, immune cells displayed decreased levels of pSTAT3, myeloid cells produced more IL-12 and IL-1β while T cells were more activated and secreted higher amounts of effector cytokinesinterferon-γ and tumor necrosis factor-α. An increase in sIL-6R was potentially associated with a survival benefit (P = 0.03). CONCLUSIONS:Functional IL-6R blocking is feasible and safe in EOC patients treated withcarboplatin/(pegylated liposomal)doxorubicin, using 8 mg/kg tocilizumab. This combination is recommended for phase II evaluation based on immune parameters. CLINICAL TRIAL REGISTER: NCT01637532.
RCT Entities:
BACKGROUND: The immune system is important in epithelial ovarian cancer (EOC). Interleukin-6 is associated with chemoresistance and an immune-suppressive tumor microenvironment. We investigated whether a combination of chemotherapeutics, blockade of interleukin 6 (IL-6) receptor (IL-6R; tocilizumab), and immune enhancer interferon-α (Peg-Intron) is feasible, safe, and able to enhance immunity in patients with recurrent EOC. PATIENTS AND METHODS: In this dose-escalation study, patients received tocilizumab 1, 2, 4, or 8 mg/kg i.v., q4 weeks during the first three cycles of carboplatin (AUC5) plus doxorubicin [pegylated liposomal doxorubicin (PLD) 30 mg/m(2) or doxorubicin 50 mg/m(2) i.v., day 1, q4 weeks, for six cycles]. At the highest tocilizumab dose (8 mg/kg), Peg-Intron (1 µg/kg s.c.) was added. Peripheral blood mononuclear cells were collected for immunomonitoring at baseline, after three and six cycles. Dose-limiting toxicity (DLT), CA-125, and radiologic response were evaluated. RESULTS: In the 23 patients enrolled, no DLT was established. The most frequent grade 3/4 adverse events (CTCAE v4.03) were neutropenia (23%), febrile neutropenia (19%), and ileus (19%). No treatment-related deaths occurred. Using CT evaluation, 11 of 21 assessable patients responded, 6 had stable disease and 3 progressive disease. Patients receiving highest dose tocilizumab showed a functional blockade of IL-6R with increased levels of serum IL-6 (P = 0.02) and soluble IL-6R (P = 0.008). Consequently, immune cells displayed decreased levels of pSTAT3, myeloid cells produced more IL-12 and IL-1β while T cells were more activated and secreted higher amounts of effector cytokines interferon-γ and tumor necrosis factor-α. An increase in sIL-6R was potentially associated with a survival benefit (P = 0.03). CONCLUSIONS: Functional IL-6R blocking is feasible and safe in EOC patients treated with carboplatin/(pegylated liposomal)doxorubicin, using 8 mg/kg tocilizumab. This combination is recommended for phase II evaluation based on immune parameters. CLINICAL TRIAL REGISTER: NCT01637532.
Authors: Marwa Ali A Fathi; Amer Ali Abd El-Hafeez; Dalia Abdelhamid; Samar H Abbas; Monica M Montano; Mohamed Abdel-Aziz Journal: Bioorg Chem Date: 2018-11-22 Impact factor: 5.275
Authors: Thomas A Mace; Reena Shakya; Jason R Pitarresi; Benjamin Swanson; Christopher W McQuinn; Shannon Loftus; Emily Nordquist; Zobeida Cruz-Monserrate; Lianbo Yu; Gregory Young; Xiaoling Zhong; Teresa A Zimmers; Michael C Ostrowski; Thomas Ludwig; Mark Bloomston; Tanios Bekaii-Saab; Gregory B Lesinski Journal: Gut Date: 2016-10-21 Impact factor: 23.059
Authors: Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi Journal: Oncoimmunology Date: 2018-02-15 Impact factor: 8.110
Authors: Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief Journal: Nat Rev Cancer Date: 2016-03-11 Impact factor: 60.716
Authors: Sham S Kakar; Christopher A Worth; Zhenglong Wang; Kelsey Carter; Mariusz Ratajczak; Pranesh Gunjal Journal: J Cancer Stem Cell Res Date: 2016-04-19